Document Detail

Short-term effectiveness of intravitreal bevacizumab versus ranibizumab injections for patients with neovascular age-related macular degeneration.
MedLine Citation:
PMID:  19934818     Owner:  NLM     Status:  MEDLINE    
PURPOSE: To compare the effectiveness of three consecutive intravitreal injections of bevacizumab (Avastin) and ranibizumab (Lucentis) in patients with treatment-naïve neovascular age-related macular degeneration.
METHODS: This is a retrospective comparative study of qualifying consecutively treated patients (n = 176) with new-onset subfoveal choroidal neovascularization presenting at 6 retina referral centers. Patients were treated with 3 consecutive monthly injections of ranibizumab (0.5 mg) or 3 injections of bevacizumab every 6 weeks (1.25 mg) as determined by physician and patient preference. Ophthalmologic evaluations included monthly visual acuity measurements, ocular examinations, and optical coherence tomography imaging at each visit.
RESULTS: A 29.2% reduction in the mean central foveal thickness measurement through optical coherence tomography was found in the ranibizumab-treated patients versus a 20.9% reduction in the bevacizumab-treated patients (P <or= 0.02). Fifty-three percent of ranibizumab-treated patients had returned to a central foveal thickness of <200 microm by the completion of 3 injections compared with 35% of patients treated with bevacizumab (P <or= 0.07). No ocular or systemic adverse events were reported in either group.
CONCLUSION: Short-term effectiveness of ranibizumab treatment, as measured by incremental improvement in optical coherence tomography parameters, was significantly greater than bevacizumab treatment, suggesting that there is a difference in the biologic activities of ranibizumab and bevacizumab.
Tom S Chang; Gregg Kokame; Raynor Casey; Jonathan Prenner; Leonard Feiner; Nick Anderson
Related Documents :
9400778 - Penalization versus part-time occlusion and binocular outcome in treatment of strabismi...
11725768 - Subretinal, viscoelastic-assisted, endoscope-guided photothermal ablation of choroidal ...
12322788 - Treatment with taurine, diltiazem, and vitamin e retards the progressive visual field r...
22162788 - Total hip arthroplasty using two-incision technique.
3304198 - The treatment of generalized peritonitis by closed postoperative peritoneal lavage. a c...
8703168 - Low-molecular-weight heparin (enoxaparin) as prophylaxis against venous thromboembolism...
Publication Detail:
Type:  Comparative Study; Journal Article; Multicenter Study    
Journal Detail:
Title:  Retina (Philadelphia, Pa.)     Volume:  29     ISSN:  1539-2864     ISO Abbreviation:  Retina (Philadelphia, Pa.)     Publication Date:  2009 Oct 
Date Detail:
Created Date:  2009-11-25     Completed Date:  2010-01-13     Revised Date:  2013-05-27    
Medline Journal Info:
Nlm Unique ID:  8309919     Medline TA:  Retina     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1235-41     Citation Subset:  IM    
Retina Institute of California, Pasadena, California 91105,
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Angiogenesis Inhibitors / administration & dosage*
Antibodies, Monoclonal / administration & dosage*
Antibodies, Monoclonal, Humanized
Choroidal Neovascularization / drug therapy*,  etiology,  physiopathology
Fluorescein Angiography
Macular Degeneration / complications,  drug therapy*,  physiopathology
Retina / pathology
Retrospective Studies
Tomography, Optical Coherence
Treatment Outcome
Vascular Endothelial Growth Factor A / antagonists & inhibitors
Visual Acuity / physiology
Vitreous Body
Reg. No./Substance:
0/Angiogenesis Inhibitors; 0/Antibodies, Monoclonal; 0/Antibodies, Monoclonal, Humanized; 0/Vascular Endothelial Growth Factor A; 0/ranibizumab; 2S9ZZM9Q9V/bevacizumab

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Intravitreal bevacizumab for treatment-naive patients with subfoveal occult choroidal neovasculariza...